Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

Clinical Cancer Research

PubMedID: 26169966

van Elsas A, van Eenennaam H, Haanen JB. Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. Clin Cancer Res. 2015;21(19):4251-3.
T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology. Clin Cancer Res; 21(19); 4251-3. ©2015 AACR. See related article by Patnaik et al. , p. 4286.